...
【24h】

A case of venlafaxine-induced bruxism alleviated by duloxetine substitution.

机译:由度洛西汀替代减轻了文拉法辛引起的磨牙症。

获取原文
获取原文并翻译 | 示例
           

摘要

Bruxism, characterized by clenching and/or grinding of dentition, is a common condition affecting 8-21% of the population (Attansio, 1997). Selective serotonin reuptake inhibitors (SSRIs) have been the most commonly reported antidepressant agents to cause bruxism and distress patients' lives (Winocur et al., 2003). The serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine, but not duloxetine, has also been reported to be associated with bruxism in sporadic cases (Alonso-Navarro et al., 2009; Jaffee and Bostwick, 2000; Brown and Hong, 1999; Kuloglu et al., 2010). To our knowledge, there has been no report on relieving bruxism symptoms with an SNRI substitution.
机译:以磨牙和/或磨牙为特征的磨牙症是影响8-21%人口的常见疾病(Attansio,1997)。选择性5-羟色胺再摄取抑制剂(SSRIs)是引起磨牙症和困扰患者生命的最普遍报道的抗抑郁药(Winocur等,2003)。 5-羟色胺-去甲肾上腺素再摄取抑制剂(SNRI)文拉法辛(而非度洛西汀)在散发性病例中也与磨牙症相关(Alonso-Navarro等,2009; Jaffee和Bostwick,2000; Brown和Hong,1999; Kuluglu)等(2010)。据我们所知,尚无关于用SNRI替代缓解磨牙症症状的报道。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号